metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-42 OBESITY AND ANTI-HBC IGG POSITIVITY INCREASE THE RISK OF HEPATOCELLULAR CAR...
Información de la revista
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 28. Núm. S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(marzo 2023)
Acceso a texto completo
P-42 OBESITY AND ANTI-HBC IGG POSITIVITY INCREASE THE RISK OF HEPATOCELLULAR CARCINOMA IN A COHORT OF CHRONIC HEPATITIS C PATIENTS IN A TERTIARY OUTPATIENT CLINIC IN SÃO PAULO, BRAZIL
Visitas
272
Alexandre Trazzi, Patricia Momoyo Zitelli, Daniel Mazo Ferraz, Roque Gabriel Rezende, Claudia Oliveira Pinto, Aline Chagas Lopes, Flair José Carrilho, Mário Guimarães Pessoa
Division of Gastroenterology, University of Sao Paulo, Sao Paulo, Brazil
Este artículo ha recibido
Información del artículo
Suplemento especial
Este artículo forma parte de:
Vol. 28. Núm S1

Abstracts of the 2022 Annual Meeting of the ALEH

Más datos
Introduction and Objectives

Chronic infection with hepatitis C virus (HCV) still affects millions of people around the world despite the recent development of very effective direct-acting antiviral (DAA) treatment. Even after a high cure rate, patients with advanced fibrosis should remain under surveillance due to the high risk of developing hepatocellular carcinoma. This study aimed to evaluate the prevalence and risk factors for hepatocellular carcinoma development in previously treated chronic HCV patients in an outpatient hepatology clinic at Clinic Hospital of the University of São Paulo of School Medicine in the city of São Paulo.

Materials and Methods

This is a retrospective, observational and descriptive study of a series of cases in which 410 HCV patients were treated with three different antiviral regiments: Interferon plus Ribavirin (INF + RBV) or Protease Inhibitors (PI) or DAA, were followed for up to ten years (2011-2021). Demographic, clinical and laboratory data were obtained for electronic medical records.

Results

the total sample of this study consists of 402 patients. Table 1 shows the patient demographic and clinical data. Of the 35 patients who developed HCC, 26 (74%) had F4-degree fibrosis. Logistic regression model was performed with the following variables: BMI (p=0.005), positive anti-HBC IgG (p=0.015), combination fibrosis and CHIILD-PUGH score A (p=0.001), B (p=0.012) and C(p< 0.001).

Conclusions

In our cohort, obesity and anti-HBc IgG were significantly associated with a high risk of developing HCC. The type of antiviral treatment (IFN or DAA-based) was not associated with the risk of HCC.

El Texto completo está disponible en PDF
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos